Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

HIV Infections in US Could be Reduced By Up to 67 Percent by 2030, Study Finds

By Georgia State University | February 22, 2019

New HIV infections in the United States could be substantially reduced by up to 67 percent by 2030 if ambitious goals for HIV care and treatment are met and targeted prevention interventions for people at risk for HIV are rapidly scaled up, according to a study by Georgia State University and the University at Albany-SUNY.

The federal administration recently announced a goal to reduce new HIV infections by 90 percent in the next 10 years during the 2019 State of the Union address. This study shows the goal is unlikely to be achieved, but that it is possible to substantially reduce new HIV infections in the next decade with innovative models for delivering HIV care and prevention interventions and sufficient investments to bring them to scale.

The researchers analyzed the latest HIV surveillance data from the Centers for Disease Control and Prevention (CDC) and estimated how many new HIV infections could be averted through ambitious, but attainable, national HIV prevention goals.

They predict that meeting internationally accepted targets for HIV diagnosis and care by 2025 and preventing an additional 20 percent of transmissions through targeted interventions such as pre-exposure prophylaxis (PrEP) for people with HIV risk would enable the U.S. to reduce new HIV infections by 67 percent in the next decade.

Achieving this goal would require the percentage of people diagnosed with HIV who are receiving care to increase from under 70 percent to 95 percent in six years and 40 percent PrEP coverage among people at risk for HIV, levels that are unprecedented in the U.S. epidemic. The results are published in the journal AIDS and Behavior.

“It is important to set HIV prevention goals that are ambitious, but realistic,” said Dr. Heather Bradley, lead author of the study and assistant professor in the School of Public Health at Georgia State. “We know that treating people living with HIV greatly improves health and also prevents transmission of HIV infection to others. However, treating enough people to meaningfully reduce new HIV infections will require us to confront issues like poverty, unstable housing and mental health conditions that keep people living with HIV from accessing care.”

Progress to reduce HIV infections in the U.S., particularly among key minority and risk groups, has been relatively stagnant, and a new national HIV strategy with achievable targets is critically needed.

“Greatly increasing the number of people living with HIV who are receiving care and treatment combined with targeted prevention strategies for people at risk for HIV infection could result in substantial reductions in new HIV infections in the next decade. Our study estimates how much improvement is possible and can help quantify what it would take to get there,” Bradley said.


Filed Under: Infectious Disease

 

Related Articles Read More >

RSV at IDWeek 2025: Competitive expansion of preventive and therapeutic modalities
Top 25 drugs by sales: 2025 H1
Bipartisan support for vaccines could be a balm for beleaguered vaccine companies
Real-world data ties COVID-19 to preterm birth risks, spotlights gaps in lung cancer treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE